THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Feb. 4, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® ...
ENBREL in the EU is approved for the following indications: Rheumatoid arthritis: ENBREL in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid ...
THOUSAND OAKS, Calif., Nov. 22, 2011 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement: Amgen today announced the issuance of U.S. Patent No. 8,063,182 related to Enbrel ® ...
THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., April 30, 2004 – Amgen (N), today announced that Enbrel® (etanercept) has been approved by the U.S. Food and Drug Ad ASDAQ: AMGN) and Wyeth ...
FDA said in briefing documents ahead of a July 13, 2016 meeting that Sandoz’s biosimilar GP2015 has “no clinically meaningful differences” with the US-licensed and EU-licensed versions of Enbrel ...
SAN FRANCISCO -- Immunex Corp. will tell doctors its popular rheumatoid arthritis drug Enbrel can treat other joint and spinal disorders, part of a strategy to expand the market for Enbrel and keep it ...
Novartis AG NVS announced that the FDA’s Arthritis Advisory Committee has recommended an approval of the company’s proposed biosimilar of Amgen’s AMGN blockbuster drug, Enbrel (etanercept). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback